Jamjoom Pharma profit rises 5% to SAR 416.1M in 9M 2026; Q3 at SAR 110.2M

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a net profit of SAR 416.1 million for the first nine months of 2026, an increase of 5% from SAR 395.7 million in the year-earlier period.

Financials (Million Riyal)

Item	9m 2025	9m 2026	Change‬
Revenues	1,196.06	1,281.36	7.1 %
Gross Income	752.18	826.91	9.9 %
Operating Income	403.45	433.64	7.5 %
Net Income	395.73	416.05	5.1 %
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyals)	5.65	5.94	5.1 %
EPS (Riyal)	5.65	5.94	5.1 %

Topline rose 7.1% year-on-year (YoY) supported by the sustained growth in Saudi Arabia, strong performance in Iraq and Gulf markets, and higher sales volumes in ophthalmology, dermatology, and cardiometabolic therapeutic areas, despite market challenges and geopolitical developments.

Gross profit margin led up due to improved production efficiency and a better product and geographic sales mix. This was partially offset by higher operating expenses to support future growth.

Current Quarter Comparison (Million Riyal)

Compared With The

Item	Q3 2025	Q3 2026	Change‬
Revenues	342.31	354.66	3.6 %
Gross Income	208.54	222.88	6.9 %
Operating Income	109.92	115.27	4.9 %
Net Income	106.67	110.21	3.3 %
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyal)	1.52	1.57	3.3 %
EPS (Riyal)	1.52	1.57	3.3 %

Item	Q2 2026	Q3 2026	Change‬
Revenues	445.31	354.66	(20.4 %)
Gross Income	293.65	222.88	(24.1 %)
Operating Income	146.00	115.27	(21.0 %)
Net Income	137.63	110.21	(19.9 %)
Average Shares	70.00	70.00	-
Earnings Per Share before unusual items (Riyal)	1.97	1.57	(19.9 %)
EPS (Riyal)	1.97	1.57	(19.9 %)

In Q3 2026, net earnings rose 3.3% to SAR 110.21 million, compared to SAR 106.67 million in Q3 2025.

On a sequential basis, net earnings fell 19.9% from SAR 137.63 million in Q2 2026.

Total shareholders’ equity, no minority interest, reached SAR 1.82 billion by Sept. 30, 2026, compared to SAR 1.65 billion in the year-earlier period.

Attached Documents

View More Financial Results

Company	Estimated	Actual
EIC	219.50	177.69
JAMJOOM PHARMA	103.87	110.21
SAIB	532.63	506.90
SAB	2,197.38	2,165.00
SAUDI KAYAN	(613.50)	(94.20)
ALDREES	129.50	137.59
SNB	6,355.62	6,450.00
RIBL	2,570.98	2,865.75
ALINMA	1,684.50	1,588.30
BJAZ	449.26	471.60

Company	Estimated	Actual
EIC	219.50	151.59
JAMJOOM PHARMA	103.87	110.21
SAIB	532.63	506.90
SAB	2,197.38	2,165.00
SAUDI KAYAN	(613.50)	(223.20)
ALDREES	129.50	137.59
SNB	6,355.62	6,450.00
RIBL	2,570.98	2,865.75
ALINMA	1,684.50	1,588.30
BJAZ	449.26	471.60

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

	Current
Market Cap (M Riyal)	8,498.00
Enterprise Value (EV) (M Riyal)	8,231.60
Shares Outstanding ((M))	70.00
Recurring EPS ( Riyal) (TTM)	6.92
Book Value (BV) ( Riyal)	26.11
Par Value ( Riyal)	10.00
Recurring P/E (TTM)	17.55
P/E (TTM)	17.55
Price/book	4.65
Dividend Yield (%) (Last Year)	3.29
Return on Average Assets (%) (TTM)	21.8
Return on Average Equity (%) (TTM)	27.8
EV/Revenues	5.19

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	701.30	-	442.77	-	171.70	-
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
Q1 2021	121.82	-	77.37	-	14.74	-
Q2 2021	193.05	-	124.75	-	49.73	-
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
Q1 2022	243.78	100.1 %	164.32	112.4 %	77.42	425.2 %
Q2 2022	238.30	23.4 %	153.06	22.7 %	57.61	15.9 %
Q3 2022	237.76	-	151.13	-	60.03	-
Q4 2022	196.84	-	125.41	-	38.26	-
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
Q1 2023	300.85	23.4 %	199.61	21.5 %	93.91	21.3 %
Q2 2023	298.40	25.2 %	198.10	29.4 %	92.56	60.7 %
Q3 2023	292.61	23.1 %	187.23	23.9 %	84.67	41.1 %
Q4 2023	208.96	6.2 %	118.91	(5.2 %)	42.24	10.4 %
2023	1,100.82	20.1 %	703.84	18.5 %	313.38	34.3 %
Q1 2024	385.46	28.1 %	249.40	24.9 %	126.58	34.8 %
Q2 2024	345.74	15.9 %	218.18	10.1 %	104.26	12.6 %
Q3 2024	327.58	11.9 %	194.41	3.8 %	95.67	13.0 %
Q4 2024	259.70	24.3 %	158.51	33.3 %	54.18	28.3 %
2024	1,318.48	19.8 %	820.50	16.6 %	380.70	21.5 %
Q1 2025	457.53	18.7 %	292.85	17.4 %	156.96	24.0 %
Q2 2025	396.22	14.6 %	250.80	14.9 %	133.39	27.9 %
Q3 2025	342.31	4.5 %	208.54	7.3 %	109.92	14.9 %
Q4 2025	304.57	17.3 %	186.63	17.7 %	63.10	16.5 %
2025	1,500.63	13.8 %	938.81	14.4 %	461.54	21.2 %
Q1 2026	481.39	5.2 %	310.38	6.0 %	172.51	9.9 %
Q2 2026	445.31	12.4 %	293.65	17.1 %	146.00	9.5 %
Q3 2026	354.66	3.6 %	222.88	6.9 %	115.27	4.9 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2018	701.30	-	442.77	-	171.70	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
2023	1,100.82	20.1 %	703.84	18.5 %	313.38	34.3 %
2024	1,318.48	19.8 %	820.50	16.6 %	380.70	21.5 %
2025	1,500.63	13.8 %	938.81	14.4 %	461.54	21.2 %

Profit Performance (Million Riyal)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	150.84	-	2.15	-	150.84	2.15
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	159.93	6.0 %	2.28	-	159.93	2.28
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	206.86	29.3 %	2.96	-	206.86	2.96
Q1 2021	10.98	-	0.16	-	10.98	0.16
Q2 2021	41.19	-	0.59	-	41.19	0.59
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
Q1 2022	43.53	296.3 %	0.62	(28.75)	72.28	1.03
Q2 2022	50.42	22.4 %	0.72	(4.27)	54.69	0.78
Q3 2022	45.60	-	0.65	(7.96)	53.56	0.77
Q4 2022	31.76	-	0.45	(6.98)	38.73	0.55
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
Q1 2023	85.71	96.9 %	1.22	-	85.71	1.22
Q2 2023	86.27	71.1 %	1.23	-	86.27	1.23
Q3 2023	75.94	66.5 %	1.08	-	75.94	1.08
Q4 2023	44.48	40.1 %	0.64	-	44.48	0.64
2023	292.40	70.7 %	4.18	-	292.40	4.18
Q1 2024	102.97	20.1 %	1.47	-	102.97	1.47
Q2 2024	106.95	24.0 %	1.53	-	106.95	1.53
Q3 2024	94.99	25.1 %	1.36	-	94.99	1.36
Q4 2024	51.61	16.0 %	0.74	-	51.61	0.74
2024	356.52	21.9 %	5.09	-	356.52	5.09
Q1 2025	157.03	52.5 %	2.24	-	157.03	2.24
Q2 2025	132.02	23.4 %	1.89	-	132.02	1.89
Q3 2025	106.67	12.3 %	1.52	-	106.67	1.52
Q4 2025	68.07	31.9 %	0.97	-	68.07	0.97
2025	463.80	30.1 %	6.63	-	463.80	6.63
Q1 2026	168.21	7.1 %	2.40	-	168.21	2.40
Q2 2026	137.63	4.2 %	1.97	-	137.63	1.97
Q3 2026	110.21	3.3 %	1.57	-	110.21	1.57

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2018	150.84	-	2.15	-	150.84	2.15
2019	159.93	6.0 %	2.28	-	159.93	2.28
2020	206.86	29.3 %	2.96	-	206.86	2.96
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
2023	292.40	70.7 %	4.18	-	292.40	4.18
2024	356.52	21.9 %	5.09	-	356.52	5.09
2025	463.80	30.1 %	6.63	-	463.80	6.63

Profitability

Period	Gross Margin	Adjusted EBITDA margin	Net Margin Before Unusual Items
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
2018	63.14 %	30.54 %	21.51 %
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
2019	57.72 %	29.63 %	21.86 %
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
2020	63.74 %	33.74 %	25.69 %
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
2021	64.52 %	28.43 %	23.20 %
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	64.79 %	28.15 %	23.92 %
2022	64.79 %	28.15 %	23.92 %
Q1 2023	64.62 %	28.21 %	23.90 %
Q2 2023	65.22 %	29.98 %	25.56 %
Q3 2023	65.25 %	30.78 %	26.33 %
Q4 2023	63.94 %	30.89 %	26.56 %
2023	63.94 %	30.89 %	26.56 %
Q1 2024	63.57 %	31.55 %	26.12 %
Q2 2024	62.76 %	31.56 %	26.80 %
Q3 2024	61.60 %	31.80 %	27.56 %
Q4 2024	62.23 %	31.71 %	27.04 %
2024	62.23 %	31.71 %	27.04 %
Q1 2025	62.13 %	32.44 %	29.53 %
Q2 2025	62.22 %	33.39 %	30.23 %
Q3 2025	62.56 %	34.14 %	30.73 %
Q4 2025	62.56 %	33.82 %	30.91 %
2025	62.56 %	33.69 %	30.91 %
Q1 2026	62.73 %	34.46 %	31.16 %
Q2 2026	63.50 %	34.34 %	30.54 %
Q3 2026	63.91 %	-	30.53 %

Period	Gross Margin	Adjusted EBITDA margin	Net Margin Before Unusual Items
2018	63.14 %	30.54 %	21.51 %
2019	57.72 %	29.63 %	21.86 %
2020	63.74 %	33.74 %	25.69 %
2021	64.52 %	28.43 %	23.20 %
2022	64.79 %	28.15 %	23.92 %
2023	63.94 %	30.89 %	26.56 %
2024	62.23 %	31.71 %	27.04 %
2025	62.56 %	33.69 %	30.91 %

Period	Gross Margin	Adjusted EBITDA margin	Net Margin Before Unusual Items
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	63.51 %	-	9.02 %
Q2 2021	64.62 %	32.15 %	21.34 %
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	67.40 %	34.26 %	29.65 %
Q2 2022	64.23 %	26.75 %	22.95 %
Q3 2022	63.56 %	27.86 %	22.53 %
Q4 2022	63.71 %	22.63 %	19.68 %
Q1 2023	66.35 %	33.30 %	28.49 %
Q2 2023	66.39 %	33.17 %	28.91 %
Q3 2023	63.98 %	31.24 %	25.95 %
Q4 2023	56.90 %	23.66 %	21.29 %
Q1 2024	64.70 %	34.80 %	26.71 %
Q2 2024	63.11 %	32.98 %	30.93 %
Q3 2024	59.35 %	32.21 %	29.00 %
Q4 2024	61.04 %	24.80 %	19.87 %
Q1 2025	64.01 %	36.54 %	34.32 %
Q2 2025	63.30 %	36.34 %	33.32 %
Q3 2025	60.92 %	35.45 %	31.16 %
Q4 2025	61.27 %	24.60 %	22.35 %
Q1 2026	64.48 %	38.44 %	34.94 %
Q2 2026	65.94 %	35.71 %	30.91 %
Q3 2026	62.84 %	-	31.07 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2018	-	-	-	-
Q2 2018	-	-	-	-
Q3 2018	-	-	-	-
Q4 2018	-	-	-	-
Q1 2019	-	-	-	-
Q2 2019	-	-	-	-
Q3 2019	-	-	-	-
Q4 2019	-	-	-	-
Q1 2020	-	-	-	-
Q2 2020	-	-	-	-
Q3 2020	-	-	-	-
Q4 2020	-	-	-	-
Q1 2021	70.00	-	-	-
Q2 2021	70.00	-	-	16.98
Q3 2021	-	-	-	-
Q4 2021	-	-	-	-
Q1 2022	70.00	-	-	17.67
Q2 2022	70.00	-	-	18.03
Q3 2022	70.00	-	-	18.34
Q4 2022	70.00	2.45	3.13	17.38
Q1 2023	70.00	3.05	3.32	18.13
Q2 2023	70.00	3.56	3.78	19.36
Q3 2023	70.00	4.00	4.09	19.45
Q4 2023	70.00	4.18	4.18	20.06
Q1 2024	70.00	4.42	4.42	20.88
Q2 2024	70.00	4.72	4.72	20.90
Q3 2024	70.00	4.99	4.99	20.64
Q4 2024	70.00	5.09	5.09	21.29
Q1 2025	70.00	5.87	5.87	22.09
Q2 2025	70.00	6.22	6.22	24.03
Q3 2025	70.00	6.39	6.39	23.61
Q4 2025	70.00	6.63	6.63	24.53
Q1 2026	70.00	6.79	6.79	24.71
Q2 2026	70.00	6.87	6.87	26.83
Q3 2026	70.00	6.92	6.92	26.11

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2018	70.00	2.15	2.15	14.28
2019	70.00	2.28	2.28	15.28
2020	70.00	2.96	2.96	16.84
2021	70.00	2.44	2.44	17.59
2022	70.00	2.45	3.13	17.38
2023	70.00	4.18	4.18	20.06
2024	70.00	5.09	5.09	21.29
2025	70.00	6.63	6.63	24.53

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	-	-	-
Q1 2023	-	-	-
Q2 2023	25.13	23.71	4.62
Q3 2023	28.98	28.28	5.95
Q4 2023	27.53	27.53	5.73
Q1 2024	28.71	28.71	6.08
Q2 2024	30.81	30.81	6.96
Q3 2024	38.19	38.19	9.24
Q4 2024	29.88	29.88	7.15
Q1 2025	26.60	26.60	7.06
Q2 2025	27.83	27.83	7.21
Q3 2025	24.66	24.66	6.68
Q4 2025	21.48	21.48	5.80
Q1 2026	20.97	20.97	5.76
Q2 2026	22.58	22.58	5.78
Q3 2026	18.25	18.25	4.83

Period	P/E	Recurring P/E	Price/book
2018	-	-	-
2019	-	-	-
2020	-	-	-
2021	-	-	-
2022	-	-	-
2023	27.53	27.53	5.73
2024	29.88	29.88	7.15
2025	21.48	21.48	5.80

Business Segments (Million Riyal)

Compared With The

Period	Pharmaceutical products	Consumer Health Products
Q1 2021	107.12	14.70
Q2 2021	174.82	18.23
Q1 2022	203.09	40.70
Q2 2022	207.60	30.70
Q3 2022	206.65	31.11
Q4 2022	180.05	16.79
Q1 2023	258.50	42.35
Q2 2023	256.14	42.26
Q3 2023	251.49	41.12
Q4 2023	190.60	18.36
Q1 2024	334.33	51.13
Q2 2024	299.43	46.30
Q3 2024	282.33	45.24
Q4 2024	223.31	36.39
Q1 2025	397.88	59.64
Q2 2025	340.71	55.52
Q3 2025	289.84	52.47
Q4 2025	255.43	49.14
Q1 2026	432.33	49.06
Q2 2026	384.78	60.53

Period	Pharmaceutical products	Consumer Health Products
2020	731.16	74.15
2021	663.46	72.22
2022	797.38	119.30
2023	956.73	144.09
2024	1,139.41	179.07
2025	1,283.86	216.77

Analysts Estimates (Million Riyal)

Item	Profit (Expected)	Profit (Actual)	Change
Average	103.87	110.21

Estimates vs Actual (Million Riyal)

Item	Profit (Expected)	Profit (Actual)
U-Capital	106.70	110.21
GIB Capital	104.00	110.21
AlJazira Capital	100.90	110.21

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Jamjoom Pharma profit rises 5% to SAR 416.1M in 9M 2026; Q3 at SAR 110.2M

Financials (Million Riyal)

Current Quarter Comparison (Million Riyal)

Quarterly Actuals vs Estimates

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Financial Ratios

Financial results (Million Riyal)

Financial results

Profit Performance (Million Riyal)

Profit Performance

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million Riyal)

Revenue by Business Segment (Latest) 2026 Q3

Analysts Estimates (Million Riyal)

Analysts Estimates

Estimates vs Actual (Million Riyal)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Jamjoom Pharma profit rises 5% to SAR 416.1M in 9M 2026; Q3 at SAR 110.2M

Financials (Million Riyal)

Current Quarter Comparison (Million Riyal)

Quarterly Actuals vs Estimates

View other reports

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Financial Ratios

Financial results (Million Riyal)

Financial results

Profit Performance (Million Riyal)

Profit Performance

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million Riyal) Q2 2026

Revenue by Business Segment (Latest) 2026 Q3

Analysts Estimates (Million Riyal)

Analysts Estimates

Estimates vs Actual (Million Riyal)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million Riyal)